LivaNova beats estimates for Q2 revenue, raises FY guidance

Livanova

06/08/2025 11:16

Overview

LivaNova Q2 2025 revenue rises 10.7%, beating analyst expectations, per LSEG data

Adjusted EPS of $1.05 beats estimates, reflecting strong operational performance

Company raises full-year 2025 guidance for revenue, adjusted EPS and free cash flow

Outlook

LivaNova raises 2025 revenue growth guidance to 8%-9% constant-currency

Company expects 2025 adjusted EPS between $3.70 and $3.80

LivaNova projects 2025 adjusted free cash flow of $140 mln to $160 mln

Company sees foreign currency as a tailwind of approximately 1% for 2025

Result Drivers

CARDIOPULMONARY DEMAND - Strong demand for consumables and Essenz Perfusion System drove Cardiopulmonary revenue growth

NEUROMODULATION PERFORMANCE - Solid performance across all regions contributed to Neuromodulation revenue increase

OPERATING MARGIN EXPANSION - Disciplined execution led to meaningful operating margin expansion, per CEO Vladimir Makatsaria

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$352.50 mln
$332.30 mln (8 Analysts)
Q2 Adjusted EPS
Beat
$1.05
$0.86 (8 Analysts)
Q2 EPS
$0.5


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for LivaNova PLC is $58.00, about 26.5% above its August 5 closing price of $42.61

The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release: ID:nBw364Dh0a

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)